 prognost factor surviv patient advanc urotheli tumor methotrex vinblastin doxorubicin cisplatin chemotherapi between februari februari patient advanc urotheli tract tumor methotrex vinblastin adriamycin doxorubicin cisplatin m-vac chemotherapi analysi prognost factor surviv first patient undertaken cox proport hazard model normal alkalin phosphatas high karnofski perform statu kp predomin long surviv year initi therapi like patient physician select patient therapi initi hemoglobin normal rang like addit patient data model clinic implic prognost factor